R. Murphy

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
R Murphy, R. Murphy, Ross T. Murphy, Roger Murphy
Publication record
34 papers · 2,022 citations · H-index 20

PAPERS

T cells recognizing a 11mer influenza peptide complexed to H‐2Db show promiscuity for peptide length
20151 citationsauthor #5
Targeted Chemoradiation in Metastatic Colorectal Cancer: A Phase I Trial of 131I-huA33 with Concurrent Capecitabine
201431 citationsauthor #11
Heteroclitic serological response in esophageal and prostate cancer patients after NY‐ESO‐1 protein vaccination
201237 citationsauthor #17
Non-Agonistic Bivalent Antibodies That Promote c-MET Degradation and Inhibit Tumor Growth and Others Specific for Tumor Related c-MET
201233 citationsauthor #7
Impact on product quality of high productive GS-CHO cell lines
20112 citationsauthor #4
Abstract 5318: Optimizing pharmacokinetics and targeting properties of recombinant anti-Lewis Y antibody hu3S193 in A431 tumor-bearing mice
20110 citationsauthor #14
Oral Presentations_Wednesday
20090 citationsauthor #24
Humoral immune responses in patients vaccinated with 1–146 HER2 protein complexed with cholesteryl pullulan nanogel
2008128 citationsauthor #9
Analysis of peripheral and local anti‐tumor immune response in esophageal cancer patients after NY‐ESO‐1 protein vaccination
200851 citationsauthor #15
Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient
200845 citationsauthor #11
A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen
200772 citationsauthor #17
Antibody response against NY‐ESO‐1 in CHP‐NY‐ESO‐1 vaccinated patients
200770 citationsauthor #16
A phase I clinical trial with monoclonal antibody ch 806 targeting transitional state and mutant epidermal growth factor receptors
200718 citationsauthor #22
T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.
2007122 citationsauthor #18
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
2007216 citationsauthor #20
HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan
2006116 citationsauthor #16
In vitro Stimulation of CD8 and CD4 T Cells by Dendritic Cells Loaded with a Complex of Cholesterol-Bearing Hydrophobized Pullulan and NY-ESO-1 Protein: Identification of a New HLA-DR15–Binding CD4 T-Cell Epitope
200642 citationsauthor #10
Pharmacokinetics and biodistribution of humanized monoclonal antibody hu3S193 in a phase I trial of patients with advanced epithelial cancers which express the Lewis-gamma antigen
20050 citationsauthor #16
Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma
200573 citationsauthor #11
Erratum: Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans (Proceedings of the National Academy of Sciences of the United States of America (July 20, 2004) 101, 29 (10697-10702))
20054 citationsauthor #10
Cellular and humoral immune responses in patients vaccinated with HER2 protein combined with a novel nanoparticle antigen delivery system of cholesteryl hydrophobized polysacharide(CHP-HER2)
20051 citationsauthor #13
Phase I Trial of 131 I-huA 33 in Patientswith Advanced Colorectal Carcinoma
200514 citationsauthor #10
APhase I Trial of HumanizedMonoclonal AntibodyA 33 in Patients with Colorectal Carcinoma : Biodistribution , Pharmacokinetics , and QuantitativeTumor Uptake
20051 citationsauthor #13
A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake
2005122 citationsauthor #13
Phase I study of CHP-HER2 polyvalent cancer vaccine, HER2 protein combined with a novel nanoparticle antigen delivery system of cholesteryl hydrophobized polysaccharides
20050 citationsauthor #7
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.
2004459 citationsauthor #10
NY-ESO-1 protein formulated With ISCOMATRIX™ adjuvant induces a broad-based immune response involving high titers of antibody, CD4+ and CD8+ T-cell responses
20030 citationsauthor #9
Generation of Anti-Idiotype Antibodies for Application in Clinical Immunotherapy Laboratory Analyses
200328 citationsauthor #4
Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
200129 citationsauthor #2
Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.
200188 citationsauthor #16
Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3.
2000112 citationsauthor #7
Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
2000107 citationsauthor #15
Neutralizing monoclonal antibody against respiratory syncytial virus
19960 citationsauthor #5
A tissue hemadsorption inhibition neutralization test for Rubella antibody.
19674 citationsauthor #1

TIMELINE

1967 4 citations

1996 0 citations

2000 219 citations

2001 117 citations

2003 28 citations

2004 459 citations

2005 215 citations

2006 158 citations

2007 498 citations

2008 224 citations

2009 0 citations

2011 2 citations

2012 70 citations

2014 31 citations

2015 1 citations

R. Murphy

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT